Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience

Background. Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial. Aim. Analysis of efficacy and safety of KRd in routine clinical practice. Materials and methods. The prospectiv...

Full description

Bibliographic Details
Main Authors: Vera A. Zherebtsova, Vladimir I. Vorobyev, Eduard G. Gemdzhian, Margarita A. Ulyanova, Mikhail V. Chernikov, Valentina L. Ivanova, Olga Yu. Vinogradova, Vadim V. Ptushkin
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2021-07-01
Series:Терапевтический архив
Subjects:
carfilzomib
lenalidomide
autologous transplant
real-life experience
relapsed/refractory multiple myeloma
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/76318/56907

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/76318/56907

Similar Items